The prurigo nodularis treatment market is projected to witness significant growth over the coming years attributing to major factors such as rising demand for better medication, increasing adoption of antihistamines, growing investment in R&D, and burgeoning demand for advanced products.

Prurigo nodularis or PN is a skin condition where hard crusty lumps form on the human skin, which itch intensely. The bumps on the skin could range in size from extremely small to around half inch in diameter. Here the total number of modules could usually vary from 2 to 200.

The treatment of Prurigo nodularis could be quite challenging since people diagnosed with the disease might respond to treatments in a different manner. Due to high intensity of the itch, patients with PN might tend to try numerous different treatments to obtain the most relief. In fact, for numerous people, usually a combination of multiple treatments might be needed find out what would work best for them.

The prurigo nodularis treatment market is segmented in terms of product type, distribution channel, and regional landscape.

In terms of product type, the overall market is classified into emollients, corticosteroids, capsaicin cream, antihistamines, and others. Among these, antihistamines segment is likely to increase at a CAGR of 5.1% over the forecast time period. The segment will witness high adoption owing to the escalating use of antihistamines during first-line therapy for the management of allergic reactions.

These products come in the form of chewable tablets, liquids, pills, capsules, as well as eye drops. Antihistamines also come in injectable forms used largely in health care settings. In addition, antihistamines is known to treat allergy symptoms such as runny and itchy eyes, nasal passages swelling, runny nose, congestion and sneezing, hives as well as other skin rashes.

With respect to distribution channel, the market for prurigo nodularis treatment is categorized into retail pharmacies, online pharmacies, and hospital pharmacies. In 2020, the hospital pharmacies segment held a market share of about 27.5%. Going forward, the segment will witness robust growth owing to increasing demand for better medication for patients. Additionally, high patient volume in hospitals will also boost the segmental growth.

From a regional frame of reference, the prurigo nodularis treatment market in North America is expected to witness substantial growth. Numerous key factors such as the growing investment in R&D, demand for advanced products, and launch of novel therapy by local players in the U.S. is fueling the business outlook. The U.S. market held a valuation of more than $200 million in 2020 and is estimated to progress at rapid pace over the projected time period.